KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Revenue (2017 - 2025)

Aquestive Therapeutics has reported Revenue over the past 9 years, most recently at $13.0 million for Q4 2025.

  • Quarterly results put Revenue at $13.0 million for Q4 2025, up 9.67% from a year ago — trailing twelve months through Dec 2025 was $44.5 million (down 22.61% YoY), and the annual figure for FY2025 was $44.5 million, down 22.61%.
  • Revenue for Q4 2025 was $13.0 million at Aquestive Therapeutics, up from $12.8 million in the prior quarter.
  • Over the last five years, Revenue for AQST hit a ceiling of $20.1 million in Q2 2024 and a floor of $2.0 million in Q2 2021.
  • Median Revenue over the past 5 years was $12.0 million (2024), compared with a mean of $11.5 million.
  • Biggest five-year swings in Revenue: soared 300.0% in 2021 and later tumbled 50.23% in 2025.
  • Aquestive Therapeutics' Revenue stood at $11.1 million in 2021, then dropped by 3.57% to $10.7 million in 2022, then rose by 23.63% to $13.2 million in 2023, then dropped by 10.14% to $11.9 million in 2024, then rose by 9.67% to $13.0 million in 2025.
  • The last three reported values for Revenue were $13.0 million (Q4 2025), $12.8 million (Q3 2025), and $10.0 million (Q2 2025) per Business Quant data.